Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

Related Articles by Review for PubMed (Select 16961428)

1.

Mechanism of action of agents used in attention-deficit/hyperactivity disorder.

Wilens TE.

J Clin Psychiatry. 2006;67 Suppl 8:32-8. Review.

PMID:
16961428
2.

Pharmacological management of attention-deficit hyperactivity disorder.

Reeves G, Schweitzer J.

Expert Opin Pharmacother. 2004 Jun;5(6):1313-20. Review.

PMID:
15163276
3.

Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.

Biederman J, Spencer T, Wilens T.

Int J Neuropsychopharmacol. 2004 Mar;7(1):77-97. Epub 2004 Jan 21. Review.

PMID:
14733627
4.

Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

Huang YS, Tsai MH.

CNS Drugs. 2011 Jul;25(7):539-54. doi: 10.2165/11589380-000000000-00000. Review. Erratum in: CNS Drugs. 2011 Nov 1;25(11):932. Dosage error in article text.

PMID:
21699268
5.

Drugs for treatment of ADHD.

[No authors listed]

Treat Guidel Med Lett. 2006 Nov;4(51):77-82. Review. No abstract available.

PMID:
17039210
6.

Dopamine vs noradrenaline: inverted-U effects and ADHD theories.

Levy F.

Aust N Z J Psychiatry. 2009 Feb;43(2):101-8. doi: 10.1080/00048670802607238. Review.

PMID:
19153917
7.

The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.

Himpel S, Banaschewski T, Heise CA, Rothenberger A.

Expert Opin Drug Saf. 2005 Mar;4(2):311-21. Review.

PMID:
15794722
8.
9.

The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.

Sallee FR.

Postgrad Med. 2010 Sep;122(5):78-87. doi: 10.3810/pgm.2010.09.2204. Review.

PMID:
20861591
10.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
11.

alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.

Arnsten AF, Scahill L, Findling RL.

J Child Adolesc Psychopharmacol. 2007 Aug;17(4):393-406. Review.

PMID:
17822336
12.

Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.

Waxmonsky JG.

Essent Psychopharmacol. 2005;6(5):262-76. Review.

PMID:
16222911
13.

Close up on atomoxetine: a nonstimulant choice for treating ADHD.

Allen C, Pitcock J.

Adv Nurse Pract. 2006 Mar;14(3):39-40, 42-3, 78. Review. No abstract available.

PMID:
16548127
14.

Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.

Kaplan G, Newcorn JH.

Pediatr Clin North Am. 2011 Feb;58(1):99-120, xi. doi: 10.1016/j.pcl.2010.10.009. Review.

PMID:
21281851
15.

Psychopharmacology of ADHD in adolescents.

Greydanus DE, Sloane MA, Rappley MD.

Adolesc Med. 2002 Oct;13(3):599-624. Review.

PMID:
12270803
16.

Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression: a review.

Patel BD, Barzman DH.

Psychiatr Q. 2013 Dec;84(4):407-15. doi: 10.1007/s11126-013-9253-7. Review.

PMID:
23443759
17.

Non-stimulant treatment of attention-deficit/hyperactivity disorder.

Pliszka SR.

CNS Spectr. 2003 Apr;8(4):253-8. Review.

PMID:
12679740
18.

Alpha-2 agonists in the treatment of attention deficit hyperactivity disorder.

Scahill L, Barloon L, Farkas L.

J Child Adolesc Psychiatr Nurs. 1999 Oct-Dec;12(4):168-73. Review. No abstract available.

PMID:
10876518
19.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
20.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk